CJC-1295GHRP-2 and CJC-1295 stimulate two separate receptors that naturally boost growthhormone (GH) release from the anterior pituitary, CJC-1295 binds to the growth hormonereleasing hormone receptor (GHRH) while GHRP-2 binds to the growth hormone secretagogue receptor1.By stimulating two different receptors in two different biochemical pathways that have the same final result, these peptides can work togethelto boost GH release from the anterior pituitary to levels that could not achieved by eithelpeptide alone.
Both GHRP-2 and CJC-1295 have been tested in a variety of animal models and have shown positive effects on muscle hypertrophy and hyperplasia, cardiac function, and theimmune system[2]-[4]. Both peptides also decrease blood sugar levels and favor leanbody mass over fat deposition5. in fact, both peptides are known to stimulate fat loss byboosting metabolisms. This reduction in adipose (fat) tissue has been linked to improvecinsulin resistance and improvement in cases of type 2 diabetes
When combined in research studies, these peptides have cooperative effects in at leastsome of the pathways noted above.Yazar hakkındaYukarıdaki literatür, Dr, E, Logan, M.D. Moleküler biyolojide.Bilimsel yolculukDr. Dominigue Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistryfrom the University of Paris Xl, ICSN, Orsay, France with Nobel Laureate Sir Derek H. RBarton as Research Advisor. He completed his Post-Doctoral Research at the Universityof California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRFanalog and also held various leadership positions involving peptide research and technologies atlpsen.Coniuchem.Redcel.and Abbott Laboratories.Dr. Bridon hasserved as a Director for Enobia (acquired by Alexion) and Neuronax and as a member ofthe Scientific Advisory Board of Svntaxin (acauired by lpsen) and Biosortia. Henow brinas 30 vears of executive and scientific leadershin experience to the EpivaxOncology team.
Dr, Dominiaue Bridon is being referenced as one of the leading scientists involved in theresearch and development of CJC-1295. in no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. Dr.Dominiaue Bridon is listed in [7] under the referenced citations.Kaynaklar1.A.Frohman,“Pulsatile secretion of growth hormone(GH)M.lonescu and L.persists during continuous stimulation by CJC-1295, a long-acting GH-releasinghormone analog,”J.Clin.Endocrinol. Metab., vol.91,no.12,pp.4792-4797,Dec2006.[PubMed]
2.D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes toattenuate the dexamethasone-induced expressions of muscle-specific ubiguitinligases, Atrogin-1 and MuRF1,”Life Sci., vol.82,no.9-10,pp.460-466,Feb.2008.[PubMed]
3.V. Bodart et al.. “dentification and characterization of a new growth hormonereleasing peptide receptor in the heart,”Circ.Res., vol.85, no.9, pp.796-802Oct. 1999.[PubMed]
4.D. D. Taub, W. J. Murphy, and D.L. Longo, “Rejuvenation of the aging thymus:growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin.Pharmacol..vol.10.no.4.pp.408-424.Aug.2010.[PubMed]
5.S.L. Teichman, A. Neale, B. Lawrence, C. Gagnon, J.-P. Castaigne, and L. A.Frohman, “Prolonged stimulation of growth hormone (GH) and insulin-ike growthfactor l secretion by CJC-1295, a long-acting analog of GH-releasing hormone, inhealthy adults,”J.Clin.Endocrinol.Metab.,vol.91,no.3, pp.799-805, Mar. 2006[PubMed]
6.B. Laferrère, A. B. Hart, and C.Y. Bowers, “Obese subjects respond to thestimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 onfood intake,”Obes. Silver Spring Md, vol.14,no.6, pp.1056-1063, Jun.2006[PMC]
7.Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & RobitailleMartin & Pellerin, lsabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan &Bridon, Dominique.(2005).hGRF1-29-Albumin Bioconjugates Activate the GRFReceptor on the Anterior Pituitary in Rats: ldentification of CJC-1295 as a LongLasting GRF Analog.[Research Gate]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
